NewLink Genetics
E414780
NewLink Genetics is a biopharmaceutical company known for developing immuno-oncology therapies and infectious disease vaccines, including holding rights to the rVSV-ZEBOV Ebola vaccine candidate.
All labels observed (1)
| Label | Occurrences |
|---|---|
| NewLink Genetics canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T4132114 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: NewLink Genetics Context triple: [rVSV-ZEBOV, licensedTo, NewLink Genetics]
-
A.
Myriad Genetics
Myriad Genetics is a biotechnology company best known for developing and commercializing genetic tests, particularly for assessing inherited cancer risk.
-
B.
Genivar Inc.
Genivar Inc. was a Canadian engineering and professional services firm that grew through acquisitions and later rebranded as WSP Global.
-
C.
Juno Therapeutics
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
D.
Verily Life Sciences LLC
Verily Life Sciences LLC is a health-focused research and technology company that develops tools and platforms to collect, organize, and analyze health data, particularly in areas like clinical research, precision health, and disease management.
-
E.
Onex Corporation
Onex Corporation is a Canadian investment management firm and private equity company known for acquiring and managing businesses across various industries.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: NewLink Genetics Target entity description: NewLink Genetics is a biopharmaceutical company known for developing immuno-oncology therapies and infectious disease vaccines, including holding rights to the rVSV-ZEBOV Ebola vaccine candidate.
-
A.
Myriad Genetics
Myriad Genetics is a biotechnology company best known for developing and commercializing genetic tests, particularly for assessing inherited cancer risk.
-
B.
Genivar Inc.
Genivar Inc. was a Canadian engineering and professional services firm that grew through acquisitions and later rebranded as WSP Global.
-
C.
Juno Therapeutics
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
D.
Verily Life Sciences LLC
Verily Life Sciences LLC is a health-focused research and technology company that develops tools and platforms to collect, organize, and analyze health data, particularly in areas like clinical research, precision health, and disease management.
-
E.
Onex Corporation
Onex Corporation is a Canadian investment management firm and private equity company known for acquiring and managing businesses across various industries.
- F. None of above. chosen
Statements (45)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| collaboratedWith |
Genentech
ⓘ
Merck & Co. ⓘ Roche ⓘ |
| conducts | clinical trials ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| developed |
HyperAcute Lung vaccine
ⓘ
HyperAcute Pancreas vaccine ⓘ immuno-oncology drug candidates ⓘ indoximod ⓘ navoximod ⓘ |
| focusesOn |
immuno-oncology therapies
ⓘ
infectious disease vaccines ⓘ small-molecule immunotherapies ⓘ vaccine-based immunotherapies ⓘ |
| foundedBy | Charles J. Link Jr. NERFINISHED ⓘ |
| hasCEO | Charles J. Link Jr. NERFINISHED ⓘ |
| hasClinicalProgram |
Ebola vaccine trials
ⓘ
combination immunotherapy trials ⓘ |
| hasIntellectualProperty |
immuno-oncology patents
ⓘ
vaccine technology patents ⓘ |
| hasPlatform | IDO pathway inhibition ⓘ |
| hasTechnology | HyperAcute cellular immunotherapy platform ⓘ |
| headquartersLocation | Ames, Iowa ⓘ |
| heldRightsTo |
rVSV-ZEBOV
ⓘ
surface form:
rVSV-ZEBOV Ebola vaccine candidate
|
| holdsRightsTo | Ebola vaccine technology licenses ⓘ |
| industry |
biopharmaceuticals
ⓘ
biotechnology ⓘ |
| listedOn | NASDAQ ⓘ |
| partneredWith |
Biomedical Advanced Research and Development Authority
ⓘ
U.S. government agencies ⓘ |
| regulatoryInteraction |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| researchArea |
checkpoint inhibition
ⓘ
metabolic pathways in cancer ⓘ |
| specializesIn |
cancer immunotherapy
ⓘ
infectious disease immunotherapy ⓘ oncology ⓘ |
| stage | clinical-stage ⓘ |
| state | Iowa ⓘ |
| therapeuticArea |
melanoma
ⓘ
pancreatic cancer ⓘ solid tumors ⓘ |
| tickerSymbol | NLNK ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: NewLink Genetics Description of subject: NewLink Genetics is a biopharmaceutical company known for developing immuno-oncology therapies and infectious disease vaccines, including holding rights to the rVSV-ZEBOV Ebola vaccine candidate.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.